

Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the y8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPy8)

William W. Motley, MD¹; Daniel Friedman, MD²; Kathryn A. Davis, MD³; Bradley S. Galer, MD¹; Nancy Wyant, BA¹; Jose A. Matta, PhD⁴; Arnold R. Gammaitoni, PharmD¹; Dennis Dlugos, MD, MSCE⁵; Martha J. Morrell, MD⁶; Jacqueline A. French, MD⁷


¹Rapport Therapeutics, Inc., Boston, MA, USA; ²New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA; ³University of Pennsylvania, Philadelphia, PA, USA; ⁴Rapport Therapeutics, Inc., San Diego, CA, USA; ¹Rapport Therap ⁵Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA; ⁶NeuroPace, Mountain View, CA, USA; ⁷New York University Comprehensive Epilepsy Center, New York, NY, USA.

Background

RAP-219: A Novel Mechanism of Action


- α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are a clinically validated therapeutic target for epilepsy
- Transmembrane AMPAR-associated regulatory proteins (TARPs) mediate AMPAR trafficking, subcellular localization, and gating¹
- TARPγ8 has distinct regional expression in the central nervous system, as it is enriched in the neocortex and mesial temporal lobe with little to no expression in the hindbrain^{1,2} (Figure 1)
- RAP-219 is a novel, potent, and selective negative allosteric modulator that binds at the interface between AMPAR and TARPγ8³ (**Figure 2**)
- RAP-219 is well tolerated and efficacious in preclinical models of seizures (Figure 3)

Figure 1. Clinical PET Image of TARPy8 Expression




Radiotracer [18F]JNJ-64511070 targets AMPAR/TARPγ8. AMPAR - AMPA receptor; PET - positron emission tomography; TARP – transmembrane AMPAR-associated regulatory protein.

Figure 2. TARPy8 on AMPA Receptor Interface Mediates Drug Binding



TARP – transmembrane AMPAR-associated regulatory protein.

Figure 3. RAP-219 Improves Seizure Outcomes in Preclinical Models Without Motoric Impairment



nearly identical (mouse pIC₅₀=9.8; rat pIC₅₀=9.9). PTZ threshold, corneal kindling, and rotarod were assessed in mouse. PTZ – pentylenetetrazol.

Responsive Neurostimulator: A Tool for Proof-of-Concept Study Design

- RAP-219 is in Phase 2A trial for the treatment of medically refractory focal onset seizures (FOS) using a novel proof-of-concept (POC) design
- A responsive neurostimulator (RNS® System, NeuroPace, Inc.) continually monitors electrographic activity from electrodes (intracranial encephalogram; iEEG) placed directly into the seizure focus or foci and is programmed by the patient's physician to detect epileptiform activity of significance including long episodes (LEs)
- LEs are:
- Organized epileptiform activity exceeding a specified duration, typically 30 sec
- Often represent electrographic seizures (EES)
- A recognized seizure biomarker demonstrated to predict antiseizure medication response^{4,5}
- Utilized in this POC study of RAP-219 to provide efficacy signal detection and enable rapid progression into registrational trials (Table 1)

Table 1. POC Study Designs for Drug-Resistant FOS

Model Attributes	Responsive Neurostimulator (RNS® System)	Photosensitivity	Transcranial Magnetic Stimulation (TMS)
Uses focal epilepsy patient population	Yes	No	No
Direct measure of drug activity	Yes Reduction in LEs	No Evoked generalized epileptiform discharges	No Provoked cortical hyperexcitability
Informs dose selection for registrational trials	Yes PK/PD data can provide measure of efficacy degree at different exposure levels	No Indirect dose response readout	No Indirect dose response readout
Enables rapid progression into registrational trials	Yes Biomarker data to inform dose and effect size	No Does not inform dose or effect size	No Does not inform dose or effect size


FOS – focal onset seizures; LE – long episode; PK/PD – pharmacokinetic/pharmacodynamic; POC – proof-of-concept.

- iEEG measures (ie, LEs, detection counts, spike rate) have been shown to correlate with clinically meaningful seizure frequency reduction (≥50% reduction)^{4,5}
- LE frequency reduction demonstrated the strongest correlation of the iEEG measures⁵
- A 30-40% reduction in LEs within 1-4 weeks of new ASM initiation was associated with >50% seizure reduction⁶

Methods

• Approximately 20 patients with an implanted RNS® System are expected to receive RAP-219 during this multicenter, open-label POC study

Figure 4. Study Design



PK – pharmacokinetic; **POC** – proof-of-concept; **RNS**® – responsive neurostimulator.

Key Inclusion Criteria

- 18-65 years old
- Medically refractory FOS
- RNS® System implanted ≥15 months before screening and:
- Stable device configuration, stimulation, and detection settings, including LE duration
- An average of ≥8 LEs per 4-week interval during the combined retrospective/ prospective baseline periods
- Concordance of ≥50% between LEs and EES
- No anticipated need for device setting changes during the study period
- ≥1 clinical seizure(s) during the retrospective baseline period

Key Exclusion Criteria

Perampanel use within 12 weeks of screening

Key Endpoints

- Change in LE frequency per 28 days during the second 4-week interval of open-label treatment period compared to frequency across retrospective and prospective baselines
- LE frequency responder analysis (percentage of patients who demonstrate ≥30% reduction in LEs)
- Change in estimated EES, clinical seizure frequency, and additional iEEG biomarkers per 28 days during the second 4-week interval of open-label treatment period compared to frequency across retrospective/prospective baseline periods
- Number of patients with clinically meaningful improvement in Patient Global Impression of Change (PGIC) and/or Caregiver Global Impression of Change (CGIC) measures
- Incidence of treatment-emergent adverse events and serious adverse events

Conclusions

- This novel POC study will enable evaluation of RNS® System measures to provide efficacy signals (biomarkers) to inform later phases of clinical development
- Analyses included in the POC study will offer insight into the efficacy of RAP-219, a novel treatment targeting TARPy8 as a precision approach for management of epilepsy

References

1. Coombs ID, et al. *Mol Pharmacol.* 2022;101(5):343-56. 2. Maher MP, et al. *J Pharmacol Exp Ther.* 2016;357(2):394-414.

3. Yu J, et al. *Nature*. 2021;594(7863):445-453.

4. Quraishi IH, et al. *Epilepsia*. 2020;61(1):138-48. 5. Skarpaas TL, et al. *Epilepsy Behav.* 2018;83:192-200. 6. Rapport, Data on file.

Acknowledgments

The authors thank Mari Willeman, PhD, and Anthony DiLauro, PhD, of PharmaWrite, LLC, for medical writing and editorial assistance, which were funded by Rapport Therapeutics, Inc.

Disclosures

WWM, BSG, NW, JAM, ARG: Rapport Therapeutics, Inc.: employee and stock ownership. DF: Epilespy Study Consortium: research services from Axcella, Biogen, Cerebel, Crossject, Engage, Eisai, Pfizer, SK Life Science, Xenon, and Zynerba. Consultant: Eisai, Neurelis Pharmaceuticals. Travel support: ČDC, NINDS, Epilepsy Foundation, Empatica, Epitel, UCB, Neuropace. Scientific advisory board: Receptor Life Sciences. KAD: Rapport Therapeutics, Inc. consultant. DD: Epilepsy Study Consortium: consulting, advisory boards/investigator meetings for Beacon Biosignals, Biohaven, Encoded, Grin Therapeutics, Jazz Pharmaceuticals, Longboard, Rapport Therapeutics, SK Life Science, Stoke, Takeda, and UCB. JAF: Epilepsy Foundation: consultant; Epilepsy Study Consortium: President, consulting, advisor boards.

